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Evidence Synthesis for Decision Making 7:
A Reviewer’s Checklist
A. E. Ades, PhD, Deborah M. Caldwell, PhD, Stefanie Reken, MSc,
Nicky J. Welton, PhD, Alex J. Sutton, PhD, Sofia Dias, PhD
This checklist is for the review of evidence syntheses for
treatment efficacy used in decision making based on
either efficacy or cost-effectiveness. It is intended to be
used for pairwise meta-analysis, indirect comparisons,
and network meta-analysis, without distinction. It does
not generate a quality rating and is not prescriptive.
Instead, it focuses on a series of questions aimed at reveal-
ing the assumptions that the authors of the synthesis are
expecting readers to accept, the adequacy of the argu-
ments authors advance in support of their position, and
the need for further analyses or sensitivity analyses. The
checklist is intended primarily for those who review evi-
dence syntheses, including indirect comparisons and
network meta-analyses, in the context of decision making
but will also be of value to those submitting syntheses for
review, whether to decision-making bodies or journals.
The checklist has 4 main headings: A) definition of the
decision problem, B) methods of analysis and presenta-
tion of results, C) issues specific to network synthesis,
and D) embedding the synthesis in a probabilistic cost-
effectiveness model. The headings and implicit advice
follow directly from the other tutorials in this series. A
simple table is provided that could serve as a pro forma
checklist. Key words: cost-effectiveness analysis; Bayesian
meta-analysis; multiparameter evidence synthesis; meta-
analysis. (Med Decis Making 2013;33:679–691)
This tutorial article sets out a practical checklistintended primarily for those who review evi-
dence syntheses, including indirect comparisons
and network meta-analyses (NMAs), in the context
of decision making. The checklist can also be used
by those preparing such evidence syntheses. It con-
sists of a set of systematic criteria by which an inde-
pendent reviewer can assess whether the synthesis
meets the requirements elaborated in the other tutor-
ials in this series.1–6
Our assumption is that the purpose of the synthe-
sis is to obtain a comparison, for purposes of efficacy
and/or cost-effectiveness, of a prespecified set of
treatments in patients with a prespecified set of char-
acteristics. The purpose of this restriction is to tie the
checklist firmly to the ‘‘decision-making’’ context in
which a clinician or the policy maker has a particular
set of patients and precisely defined treatments in
mind. This is the level at which reimbursement
authorities typically operate and in which clinicians
are interested. However, not all evidence synthesis is
conceived in precisely this way. A number of system-
atic reviews and meta-analyses are carried out with
a primary objective of summarizing literature on
a particular treatment comparison or set of compari-
sons, often in a broader range of patient groups. The
proposed checklist is not primarily intended for
that broader form of review, although itmay be highly
relevant to it.
Wemake no attempt to produce a summary quality
rating of the synthesis. A numerical or qualitative rat-
ing does not provide the information that decision
makers require to determine whether a submitted
synthesis represents an adequate basis for the deci-
sion they are charged with making. Similarly,
a numerical or quality rating does not help an edito-
rial board decide whether to accept a paper based
on an evidence synthesis. Instead, we see the check-
list as a way of assessing whether the synthesis and
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the conclusions drawn from it are a fair reflection of
what can be concluded from the existing evidence,
whatever its quality. The completed checklist would
form the basis of a reviewer report to the decision
maker or journal editor. However, the checklist also
tells those submitting a synthesis precisely what are
the critical issues they will be expected to clarify,
what arguments and evidence they may be called
upon to marshal, and the sensitivity analyses they
may be asked to undertake.
Our objective is to provide a framework for open
discussion of whether a convincing argument has
been made, albeit based on data that may be limited
and imperfect. Similarly, there is no attempt to quan-
tify the ‘‘strength of evidence’’ or suggest a ‘‘strength
of recommendation.’’7,8 A convincing argument can
be developed from poor evidence, and the strength
of evidence should be fully reflected in the credible
interval attached to it, which should incorporate
not only sampling error but uncertainty due to bias
adjustment or due to the uncertain relevance of
the available data.3 If decisions are based on cost-
effectiveness, the strength of recommendation is bet-
ter expressed through the commonly used metrics
such as incremental cost-effectiveness ratios, cost-
effectiveness acceptability curves, and probability
that a strategy is optimal, given the model and
a threshold willingness to pay.9
RELATION TO OTHER CHECKLISTS
Throughout this tutorial series, we have defined
NMA as an extension of pairwise meta-analysis.2 A
key assumption is that for any pair of treatments
under consideration, the true relative treatment
effects are either identical (fixed effect model) or
exchangeable (random effect [RE] model), across all
the trials in the set. This identity or exchangeability
requirement is present for any pair of treatments X
and Y. It is therefore not strictly correct to claim
that NMA requires extra assumptions of ‘‘trial simi-
larity’’ and ‘‘consistency,’’ additional to assumptions
that are required in pairwise meta-analysis, as has
been occasionally claimed.10–12 But this is not to
say that these properties are unimportant. On the con-
trary, the fact that pairwise and network meta-
analysis are so close in their underlying assumptions
only serves to emphasize that all the ‘‘good-practice’’
advice that is incorporated in existing guidance13,14
and checklists15–17 available for pairwise meta-
analysis is also the essential guarantor of adequacy
inNMA. Equally, it highlights that these assumptions
deserve scrutiny in the context of pairwise synthesis,
particularly as there is even less possibility of check-
ing them within the data at hand.
Rather than duplicate existing guidelines for con-
ducting or reporting systematic reviews,13,17,18 we
assume that these have been followed. Most items in
the proposed checklist apply to both pairwise and net-
work meta-analyses. The only issues that come exclu-
sively under the heading of network synthesis are
connectedness of networks, inconsistency, and soft-
ware implementation. Setting these aside, our checklist
tends to bemore restrictive than existing guidelines in
handling effect modifiers and potential effect modi-
fiers, as this is likely to be inherent in thedecision ques-
tion. In other respects, our approach is less restrictive,
in that we would encourage syntheses of multiple out-
comes within a single coherent model19–22 rather than
a separate synthesis for each outcome.
Although this checklist covers similar items to that
of the International Society for Pharmacoeconomics
and Outcomes Research (ISPOR) taskforce,23,24 it
has been designed to be more suited to inform an
actual decision-making process rather than guide
academic paper submissions.
HOW TO INTERPRET AND USE THE CHECKLIST
Our objective in providing a checklist is to provide
guidance on what questions should be asked of an
evidence synthesis by a reviewer or any other reader.
The suggested checklist expresses a record of ‘‘fact’’
about a synthesis, as well as its conduct and assump-
tions, but also provides room for comments. These
may include expressions of doubt about assumptions
or interpretations of evidence and may point to the
need for further analyses or sensitivity analyses.
In certain cases, relatively strong assumptionsmay
be necessary due to the lack of evidence. Further-
more, empirical approaches to testing those assump-
tionsmay be limited by the data available. A thorough
and transparent discussion of all assumptions and
their implications should be provided. The checklist
allows the reviewer to comment on whether the
assumptions are reasonable and adequately justified
and to indicate whether the issue in question has
been adequately addressed. For example, in reply to
a question on whether additional modeling assump-
tions were made, the reviewer may answer with
a ‘‘tick’’ adding comments such as ‘‘no additional
assumptions’’ or ‘‘additional assumptions justified’’
or put a ‘‘cross’’ with a comment indicating that the
assumptions are questionable.
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The checklist comes in 4 sections. It begins with
a set of considerations relating to the definition of
the decision problem, comparators, and target patient
population or populations, but also what is already
known about the potential role of known or unknown
effect modifiers. The second section turns to the data
analysismethods and to the results. The third section
examines issues specific to NMA: connectedness and
inconsistency. A final section touches on uncertainty
propagation in the cost-effectiveness analysis (CEA).
We refer to the other tutorials in this series through-
out for further details. A downloadable version of
the checklist is available from www.nicedsu.org.uk.
The checklist has been tested on published net-
work meta-analyses—the checklist was easy to use,
and problems with the methodology and/or the
patient population used in the reports were success-
fully identified.
THE CHECKLIST
A. Definition of the Decision Problem
A1. Target Population for Decision
A1.1. Has the target patient population for decision been
clearly defined?
Reviewers should note whether the target popula-
tion is clearly defined andwhether there is more than
1 population and, therefore, more than 1 decision
involved. Each decision would require its own CEA.
A2. Comparators
A2.1. Decision comparator set: Have all the appropriate
treatments in the decision been identified?
The decision comparator set of treatments
includes all the treatments to be compared, as identi-
fied in the scoping exercise.1,25 Ideally, this should
include all the candidate treatments for the target
population in question.
A2.2. Synthesis comparator set: Are there additional
treatments in the synthesis comparator set that are
not in the decision comparator set? If so, is this ade-
quately justified?
The synthesis comparator set consists of all
the treatments in the decision set plus any other treat-
ments used in the synthesis.1,25 One reason for add-
ing treatments to the synthesis set might be to make
a connected network.1,26 It is sometimes possible to
extend the comparison set still further,27 although
this should not be regarded as the base-case analysis.
The advantages of this extension are the increased
potential to check consistency, the potential to
reduce uncertainty by including more evidence,
and the fact that the final results will be more robust
and less sensitive to the inclusion of any individual
trial. The potential disadvantage is increased risk of
heterogeneity in patient populations. If expansion of
the network leads to increased heterogeneity, this
may result in increased uncertainty in estimates from
RE models.28 The increased uncertainty may be an
appropriate reflection of the true state of affairs, and
the increased robustness conferred by a larger ensem-
ble of data may be seen as outweighing this. Another
reason for extending the set of comparators is to be
able to include trials that provide additional informa-
tion on the relationship between outcomes.5
A3. Trial Inclusion/Exclusion
A3.1. Is the search strategy technically adequate and
appropriately reported?
To minimize bias in the systematic review, a thor-
ough search of the literature should be conducted.
This should be reported in sufficient detail so that it
can be judged and reproduced, if required.13Methods
for review protocols and reporting should be adopted
according to current best practice.13,17,18
A3.2. Have all trials involving at least 2 of the treatments
in the synthesis comparator set been included?
If some have been excluded, which are they, and
have adequate reasons been given? Should sensitivity
to inclusion/exclusion of these studies individually
and/or together be provided?
There is no specific reason to rule out trials on the
basis of their size or design, for example, because they
were noninferiority trials. All things being equal,
these design features should have no impact on the
validity of the estimates obtained, only their vari-
ance.25 Possibly, a case could be made for ruling out
smaller trials if there was reason to suspect publica-
tion bias or small-study bias, but this should be based
on a formal analysis, with examination of funnel
plots or other methods.3,29,30 Crossover or cluster-
randomized trials should also be included if they
have been analyzed and reported appropriately.
Trials that were stopped early (under a protocol
with prespecified early stopping rules) should also
be included, without adjustment for early stop-
ping.31,32 Multiarm trials involving at least 2 of the
treatments in the synthesis comparator set should
also be included. Treatments outside the synthesis
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comparator set can be excluded, as they contribute
nothing to the analysis. Single-arm studies cannot
be included in a relative efficacy analysis.
A3.3. Have all trials reporting relevant outcomes been
included?
If different trials report different but clearly related
outcomes or the same outcome has been reported in
different ways (e.g., as hazard ratios or median time
to an event) or at different time points, a synthesis
incorporating different reporting formats or test
instruments within a single coherent model should
be undertaken. Methods for combining data reported
in different formats, such as shared parameter mod-
els,2 should be considered.19,21
A3.4. Have additional trials been included? If so, is this
adequately justified?
Trials that would not fall within the strict target
definition of patients or treatments may be included,
if the trial population, treatment protocol, or dosing is
‘‘similar’’ to those within the decision problem. The
key assumption, that the relative treatment effects
are identical or exchangeable with those in the target
population, must be explicitly addressed,3 and sensi-
tivity analyses excluding these studies should be
considered. If further trials have been included, it
needs to be established that there has been no arbi-
trary selection from among a set of eligible trials.
A4. Treatment Definition
A4.1. Are all the treatment options restricted to specific
doses and co-treatments, or have different doses and
co-treatments been ‘‘lumped’’ together? If the latter, is
it adequately justified?
In a decision-making context, the doses and treat-
ment regimes being considered for every treatment in
the decision set are almost always tightly defined.1,26
The practice of ‘‘lumping’’33 doses or co-treatments
together generally makes no sense in decision making,
unless the variations in dose or co-treatment are so
small that clinicians would agree that the variation
has no material impact on efficacy.4 Lumping over dif-
ferent doses or co-treatments introduces heterogeneity
and inconsistency.34–38 If different doses or different
co-treatments are considered to have the same efficacy,
this should be explicitly addressed and justified.3
A4.2. Are there any additional modeling assumptions?
It is open to investigators to fit, for example, dose-
responsemodels39 or to fit models in which the effect
of a complex intervention can be derived from the
effects of the subcomponents.40 Evidence in the liter-
ature that bears on the validity of such models in the
current context should be reviewed and their a priori
clinical or scientific plausibility discussed. Evidence
in the form of goodness of fit of alternative models
should be presented.2
A5. Trial Outcomes and Scale of Measurement
Chosen for the Synthesis
A5.1. Where alternative outcomes are available, has the
choice of outcome measure used in the synthesis
been justified?
Several different outcomesmay be reported in a set
of trials and at more than 1 follow-up time. If a single
outcome or follow-up time is selected, this should be
justified. A coherent synthesis of several outcomes
should give more robust results (e.g., probit or logit
models for ordered categorical outcomes2), but the
validity of such models should be established by cit-
ing previous literature and/or by examining their val-
idity and goodness of fit.2
A5.2. Have the assumptions behind the choice of scale
been justified?
The choice of outcome measure that forms the
basis for the synthesis (e.g., log odds ratio, log relative
risk, log hazard ratio, risk difference) should be justi-
fied, as there is a strong assumption that the true
effects are linear on the chosen scale.2 Analysis of
rate outcomes in most cases assumes constant haz-
ards over time in each trial arm and a proportional
hazards treatment effect. The plausibility of constant
hazards, particularly when trial follow-up times vary
greatly, needs to be discussed. Conversely, the use of
logit models for probability outcomes in studies with
different follow-up times implies very different
assumptions.One option is to assume that all outcome
events that are going tooccurwill have occurredbefore
the observation period in the trial has ended, regard-
less of variation between studies in follow-up time.
Another is to assume a proportional odds model,
which implies a complex form for the hazard rates.41
The clinical plausibility of these assumptions should
be discussed and supported either by citing relevant
literature or by examination of evidence on changes
in outcome rate over the period of follow-up.
A6. Patient Population: Trials with Patients out-
side the Target Population
A6.1. Do some trials include patients outside the target
population? If so, is this adequately justified?
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A6.2. What assumptions are made about the impact or
lack of impact this may have on the relative treatment
effects? Are they adequately justified?
A6.3. Has an adjustment been made to account for these
differences? If so, comment on the adequacy of the
evidence presented in support of this adjustment
and on the need for a sensitivity analysis.
Some trials have a patient population that differs
somewhat from the target population for decision. If
these trials are included, investigators must be
explicit about what they are assuming and give a rea-
soned argument justifying their approach. One alter-
native is to say that the patients may have different
characteristics, but that would not be expected to
affect the treatment effects. The other is to include
some form of adjustment in the analysis, to obtain
an adjusted estimate that would represent the treat-
ment effect expected in the target population. This
adjustment could be based on data from another trial
or cohort study, expert elicitation,42 meta-regres-
sion,3 or a bias adjustment model.3,42–45
A7. Patient Population: Heterogeneity within the
Target Population
A7.1. Have potential modifiers of treatment effect been
considered?
This may be based on clinical opinion or on a sep-
arate review of the literature.
A7.2. Are there apparent or potential differences
between trials in their patient populations, albeit
within the target population? If so, has this been ade-
quately taken into account?
Although the patient population of every trial
appears to lie within the definition of the target pop-
ulation, there may still be heterogeneity between the
trial populations—perhaps based on age, referral pat-
tern, previous treatment, or disease severity. One
option for the investigator is to consider that neither
the relative treatment nor the baseline treatment
effects are influenced by the patient heterogeneity.
A second option is that the relative effects remain
unchanged, but baseline effects are different. This
would lead to a form of subgroup analysis on base-
lines and potentially to different decisions being
taken for different patient groups (see section B3). A
final possibility would be that the relative effects
vary. This would lead, potentially, to a subgroup
analysis based on a covariate that modified the treat-
ment effect.3 This would require discussion of any
a priori clinical rationale for a subgroup effect and
empirical evidence for it in the literature.
A8. Risk of Bias
A8.1. Is there a discussion of the biases to which these
trials, or this ensemble of trials, are vulnerable?
A8.2. If a bias risk was identified, was any adjustment
made to the analysis and was this adequately
justified?
An account should be given of the characteristics
of each of the individual trials that could be associ-
ated with bias and also the possibility of publication
or small-study biases attaching to the ensemble of tri-
als. There should also be an account of the potential
impact trial quality could have on the synthesis
results.46 Biases associated with indicators of trial
quality are a particular concern, as these may act to
increase treatment effect.47–52 Methods for adjusting
for these biases should be considered.3
A9. Presentation of the Data
A9.1. Is there a clear table or diagram showing which
data have been included in the base-case analysis?
A network diagram is a useful way of showing the
structure of the evidence. The actual data used in the
base-case analysis (trial first author and date, out-
comes, treatments compared, and covariates if rele-
vant) should be set out in a table. Good practice
examples are given in other tutorials in this series
and their appendices.1,2,4
A9.2. Is there a clear table or diagram showing which
data have been excluded and why?
Details of all trials and outcomes not considered
for the analysis should be detailed in a table or dia-
gram, alongwith reasons.17 In the interest of transpar-
ency, a note should be made of other potentially
relevant data available, such as information on
related outcomes, outcomes reported at more than
one time point, or survival curves.
B. Methods of Analysis and Presentation of Results
B1. Meta-Analytic Methods
B1.1. Is the statistical model clearly described?
Reviewers should be provided with a precise
description of the meta-analytic method used. The
model should either be presented in algebraic form,
or a citation should be provided to the statistical
model being assumed. If a Bayesian analysis is
used, details on priors, convergence, and number of
iterations should also be given.14
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Reviewers should check that the meta-analysis
method used is statistically sound for the data set at
hand.Forexample, theadditionof0.5 to zerocell counts
canmaterially bias the estimated treatment effects. If the
treatment effects are strong and the event is common or
there is large sample size imbalancebetween the groups,
the Peto method should be avoided.13 Fixed effect esti-
mators shouldnot be usedwithout considering possible
heterogeneity. Further guidance is provided in standard
texts on meta-analysis.53–55
B1.2. Has the software implementation been documented?
The name of the software module and package
used for statistical analysis should be given, and
any additional computer code should be provided,
to ensure that analyses can be replicated. If confiden-
tiality issues exist, fictitious data can be used.
B2. Heterogeneity in the Relative Treatment
Effects
B2.1. Have numerical estimates been provided of the
degree of heterogeneity in the relative treatment effects?
An assessment should bemade of the degree of het-
erogeneity in relative treatment effects for each set of
pairwise comparisons. Tests of the null hypothesis of
homogeneity,13 the I2 statistic,56 or estimates of the
between-trial variation in an RE model are useful.
The latter are particularly valuable as they can be
compared with the estimated treatment effects.3
B2.2. Has a justification been given for choice of random
or fixed effect models? Should sensitivity analyses be
considered?
The results of such analyses can be used, in part, to
justify the choice of REmodels. In a Bayesian context,
deviance information criterion statistics can also be
used for this.2
B2.3.Has therebeenanadequate response toheterogeneity?
If there is substantial heterogeneity in relative
treatment effects, the role of known or unknown
covariates and potential for random biases, as well
as the possible role of bias adjustment or control for
variation by covariate adjustment, should be dis-
cussed.3 Covariate adjustment will usually have
implications for the decision question as it raises
the possibility of different treatment effects in differ-
ent patient groups.
B2.4. Does the extent of unexplained variation in rela-
tive treatment effects threaten the robustness of
conclusions?
As the between-studies standard deviation
approaches the average treatment effect in magnitude,
it is legitimate to ask how this affects the validity of
conclusions. One might be confident that the mean
treatment effect in an RE model is greater than zero
while still being quite uncertain about whether the
treatment effect will be positive in a future instance.3
To interpret such heterogeneity in a decision context,
one suggestion is that the predictive distribution of the
treatment effect in a new trial is the appropriate input
in a decision analysis, rather than the mean effect.3,57–
59 This could be considered to better represent the
uncertainty in the treatment effect, without materially
changing the expected treatment effect.
B2.5. Has the statistical heterogeneity between baseline
arms been discussed?
The extent of heterogeneity in the baseline arms
should be discussed, as it may provide information
on the heterogeneity of the patient populations. Het-
erogeneity in baselines should lead to reexamination
of trial inclusion criteria and the risk of heteroge-
neous treatment effects.
B3. Baseline Model for Trial Outcomes
B3.1. Are baseline effects and relative effects estimated
in the same model? If so, has this been justified?
In this tutorial series,5 we have strongly recommen-
ded that the model for the relative treatment effects is
independent of the model for the baseline model. The
intention is to avoid biasing the relative effect model
by choosing a baseline model whose assumptions are
not correct. The Bayesian approach presented2 is
based on the likelihoods of the trial arms rather than
likelihoods of relative effects. Vague unrelated priors
are assumed for the ‘‘baseline’’ arm of each trial, and
the relative effects are modeled. Simultaneous model-
ing of baseline and relative effects should generally be
avoided unless a clear reason can be given.5
B3.2. Has the choice of studies used to inform the base-
line model been explained?
The source of data used for the baseline model
should be explained and justified.5 Use of the pla-
cebo arms from the available studies or from a suit-
able subset of the included studies are 2 options,
but external data could also be considered. The
source, or sources, of data that best represent the out-
come thatwould be obtainedwith the standard treat-
ment in the target population should be used. If
several sources of data are available, methods for
averaging them should be justified. Where
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heterogeneous data are used, the use of the predic-
tive distribution should be considered.5
B4. Presentation of Results of Analyses of Trial Data
B4.1. Are the relative treatment effects (relative to a pla-
cebo or ‘‘standard’’ comparator) tabulated, alongside
measures of between-study heterogeneity if an RE
model is used?
B4.2. Are the absolute effects on each treatment, as they
are used in the CEA, reported?
Guidance on what results should be presented is
available in the tutorials in this series.1–3 A table
with the results based only on direct evidence and
on the full network analysis is very informative,38
as are other graphical and tabular displays60,61 such
as rank-o-grams,22,62 which plot the probabilities
that each treatment is the best, second best, and so on.
B5. Synthesis in Other Parts of the Natural History
Model
The relative treatment effect model and the base-
linemodel are both based on the short-term outcomes
that are reported in trials. However, in most CEA
models, there is a need to project this ‘‘downstream’’
so that the natural history reflects posttrial outcomes.
B5.1. Is the choice of data sources to inform the other
parameters in the natural history model adequately
described and justified?
B5.2. In the natural history model, can the longer-term
differences between treatments be explained by their
differences on randomized trial outcomes?
Construction and interpretation of natural history
models are greatly facilitated when the values of
parameters ‘‘downstream’’ from the trial outcomes
are independent of treatment. When these parameters
do depend on treatment, they will often be informed
from observational evidence. The use of observational
evidence to drive differences in relative treatment
effects needs to be carefully justified and explained.
Potential sources of bias should be discussed.
C. Issues Specific to Network Synthesis
The need for a detailed description of the methods
and software implementation applies equally to indi-
rect comparisons and NMA.
C1. Adequacy of Information on Model Specifica-
tion and Software Implementation
For NMA and indirect comparisons, theWinBUGS
code for Bayesian evidence synthesis set out in this
series2 is a recommended option. TheSTATApackage
mvmeta63 and implementation in SAS64 are also
recommended.
Technical note: parameterization of treatment ef-
fects. There is a wide variety of alternative software
platforms suitable for use. These range from imple-
mentations in well-known statistical packages, such
as SAS, STATA, S-PLUS, or R, or variants of theWin-
BUGS coding suggested in this series.2 However, the
model parameterization requires care, as a number of
apparently innocuous variations may give very differ-
ent results or be wrong. The reviewer faced with un-
cited models or software devised by the investigator
may need to ask for further information.6
C2. Multiarm Trials
C2.1 If there are multiarm trials, have the correlations
between the relative treatment effects been taken
into account?
When the empirical treatment differences are used
as data (e.g., log odds ratios, log hazard ratios), these
will be correlated in multiarm trials and the likeli-
hoodmust be adjusted.65 This is done in the Bayesian
models2 and in STATA’s package mvmeta.63 A num-
ber of software tools now under development within
a frequentist framework are based on the treatment
differences, and it remains to be seen whether the
appropriate adjustments will be made.
C3. Connected and Disconnected Networks
C3.1. Is the network of evidence based on randomized
trials connected?
It is easy to check that a network is ‘‘connected,’’
and this should be clear from a network diagram.
The approach to network synthesis described in
this tutorial series2 is intended only for connected
networks. Approaches used to reconnect networks
require strong assumptions that must be explained
and justified.1
C4. Inconsistency
C4.1. How many inconsistencies could there be in the
network?
The network structure should be presented in
a diagram1,2,4 and the number of possible inconsis-
tencies set out.
C4.2. Are there any a priori reasons for concern that
inconsistency might exist, due to systematic clinical
differences between the patients in trials comparing
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treatments A and B, the patients in trials comparing
treatments A and C, and so on?
If theAB trials tend to have been carried out on sys-
tematically different patient populations to the AC
trials or the BC trials, there is a high risk that indirect
or mixed (direct and indirect) treatment comparisons
will be unreliable.
C4.3. Have adequate checks for inconsistency been made?
Different methods to check for inconsistency
should be used, depending on the structure of the net-
work.4ABayesian cross-validation approach can also
be used to detect the presence of outliers.30
C4.4 If inconsistency was detected, what adjustments
were made to the analysis, and how was this
justified?
If there is evidence for inconsistency in a network,
it is unlikely to form a reliable basis for choosing the
most effective or cost-effective treatment. A range of
options are available, including removing trials
from the network or incorporating additional param-
eters to account for bias. There are, however, likely to
be a large number of ways of eliminating inconsis-
tency, which all have quite different implications.4
D. Embedding the Synthesis in a Probabilistic Cost-
Effectiveness Analysis
D1. Uncertainty Propagation
D1.1. Has the uncertainty in parameter estimates been
propagated through the CEA model?
Failure to take account of the uncertainty in any
parameter should be explained and justified.
D2. Correlations
D2.1 Are there correlations between parameters? If so,
have the correlations been propagated through the
CEA model?
Correlations between parameters are induced
when they are estimated from the same data. Relative
treatment effects from networks with loops are
always correlated. Absolute effects of treatments
based on differences from a common baseline are
also correlated. Correlations must be adequately
propagated through thedecisionmodel, eitherwithin
Bayesian Markov chain Monte Carlo or frequentist
frameworks.6
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APPENDIX
Table A1. Checklist Table
MarkU to indicate that the issue has been addressed satisfactorily and if there is any cause for concern on the
item. The Comments column should be used to answer the question (YES, NO, NA: not applicable) and/or to
spell out the reasons for any concerns, the need for sensitivity analyses, and so on.
Item
Satisfactory? Comments
A. DEFINITION OF THE DECISION PROBLEM
A1. Target Population for Decision
A1.1 Has the target patient population for decision been clearly
defined?
A2. Comparators
A2.1 Decision comparator set: Have all the appropriate treatments in
the decision been identified?
A2.2 Synthesis comparator set: Are there additional treatments in the
synthesis comparator set that are not in the decision comparator
set? If so, is this adequately justified?
A3. Trial Inclusion/Exclusion
A3.1 Is the search strategy technically adequate and appropriately
reported?
A3.2 Have all trials involving at least 2 of the treatments in the syn-
thesis comparator set been included?
A3.3 Have all trials reporting relevant outcomes been included?
A3.4 Have additional trials been included? If so, is this adequately
justified?
A4. Treatment Definition
A4.1 Are all the treatment options restricted to specific doses and co-
treatments, or have different doses and co-treatments been
‘‘lumped’’ together? If the latter, is it adequately justified?
A4.2 Are there any additional modeling assumptions?
A5. Trial Outcomes and Scale of Measurement Chosen for the Synthesis
A5.1 Where alternative outcomes are available, has the choice of out-
come measure used in the synthesis been justified?
A5.2 Have the assumptions behind the choice of scale been justified?
A6. Patient Population: Trials with Patients outside the Target Population
A6.1 Do some trials include patients outside the target population? If
so, is this adequately justified?
A6.2 What assumptions are made about the impact or lack of impact
this may have on the relative treatment effects? Are they ade-
quately justified?
A6.3 Has an adjustment been made to account for these differences? If
so, comment on the adequacy of the evidence presented in sup-
port of this adjustment and on the need for a sensitivity analysis.
A7. Patient Population: Heterogeneity within the Target Population
A7.1 Have potential modifiers of treatment effect been considered?
A7.2 Are there apparent or potential differences between trials in their
patient populations, albeit within the target population? If so, has
this been adequately taken into account?
A8. Risk of Bias
A8.1 Is there a discussion of the biases to which these trials, or this
ensemble of trials, are vulnerable?
A8.2 If a bias risk was identified, was any adjustment made to the




APPENDIX Table A1. (continued)
Item
Satisfactory? Comments
A9. Presentation of the Data
A9.1 Is there a clear table or diagram showing which data have been
included in the base-case analysis?
A9.2 Is there a clear table or diagram showing which data have been
excluded and why?
B. METHODS OF ANALYSIS AND PRESENTATION OF RESULTS
B1. Meta-Analytic Methods
B1.1 Is the statistical model clearly described?
B1.2 Has the software implementation been documented?
B2. Heterogeneity in the Relative Treatment Effects
B2.1 Have numerical estimates been provided of the degree of het-
erogeneity in the relative treatment effects?
B2.2 Has a justification been given for choice of random or fixed effect
models? Should sensitivity analyses be considered?
B2.3 Has there been adequate response to heterogeneity?
B2.4 Does the extent of unexplained variation in relative treatment
effects threaten the robustness of conclusions?
B2.5 Has the statistical heterogeneity between baseline arms been
discussed?
B3. Baseline Model for Trial Outcomes
B3.1 Are baseline effects and relative effects estimated in the same
model? If so, has this been justified?
B3.2 Has the choice of studies to inform the baseline model been
explained?
B4. Presentation of Results of Analyses of Trial Data
B4.1 Are the relative treatment effects (relative to a placebo or ‘‘stan-
dard’’ comparator) tabulated, alongside measures of between-
study heterogeneity if an RE model is used?
B4.2 Are the absolute effects on each treatment, as they are used in the
CEA, reported?
B5. Synthesis in Other Parts of the Natural History Model
B5.1 Is the choice of data sources to inform the other parameters in the
natural history model adequately described and justified?
B5.2 In the natural history model, can the longer-term differences
between treatments be explained by their differences on ran-
domized trial outcomes?
C. ISSUES SPECIFIC TO NETWORK SYNTHESIS
C1. Adequacy of Information on Model Specification and Software Implementation
C2. Multiarm Trials
C2.1 If there are multiarm trials, have the correlations between the
relative treatment effects been taken into account?
C3. Connected and Disconnected Networks
C3.1 Is the network of evidence based on randomized trials connected?
C4. Inconsistency
C4.1 How many inconsistencies could there be in the network?
C4.2 Are there any a priori reasons for concern that inconsistency
might exist, due to systematic clinical differences between the
patients in trials comparing treatments A and B, the patients in
trials comparing treatments A and C, and so on?
C4.3 Have adequate checks for inconsistency been made?
(continued)
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